CN114947138A - 一种预防与改善钙缺乏病的乳钙组合物、其制法及应用 - Google Patents
一种预防与改善钙缺乏病的乳钙组合物、其制法及应用 Download PDFInfo
- Publication number
- CN114947138A CN114947138A CN202210572582.5A CN202210572582A CN114947138A CN 114947138 A CN114947138 A CN 114947138A CN 202210572582 A CN202210572582 A CN 202210572582A CN 114947138 A CN114947138 A CN 114947138A
- Authority
- CN
- China
- Prior art keywords
- parts
- calcium
- powder
- milk
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011575 calcium Substances 0.000 title claims abstract description 82
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 82
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 81
- 239000008267 milk Substances 0.000 title claims abstract description 60
- 235000013336 milk Nutrition 0.000 title claims abstract description 59
- 210000004080 milk Anatomy 0.000 title claims abstract description 59
- 206010006956 Calcium deficiency Diseases 0.000 title claims abstract description 47
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 25
- 239000000843 powder Substances 0.000 claims abstract description 96
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 36
- 239000011707 mineral Substances 0.000 claims abstract description 36
- 244000075850 Avena orientalis Species 0.000 claims abstract description 29
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 29
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 29
- 241000283690 Bos taurus Species 0.000 claims abstract description 28
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 27
- 240000005662 Aronia melanocarpa Species 0.000 claims abstract description 27
- 235000007425 Aronia melanocarpa Nutrition 0.000 claims abstract description 27
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 27
- 235000005805 Prunus cerasus Nutrition 0.000 claims abstract description 27
- 244000207449 Prunus puddum Species 0.000 claims abstract description 27
- 235000009226 Prunus puddum Nutrition 0.000 claims abstract description 27
- 210000003022 colostrum Anatomy 0.000 claims abstract description 27
- 235000021277 colostrum Nutrition 0.000 claims abstract description 27
- 240000001462 Pleurotus ostreatus Species 0.000 claims abstract description 26
- 235000001603 Pleurotus ostreatus Nutrition 0.000 claims abstract description 26
- 239000002994 raw material Substances 0.000 claims abstract description 25
- 235000008939 whole milk Nutrition 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 208000024891 symptom Diseases 0.000 claims abstract description 9
- 102000004407 Lactalbumin Human genes 0.000 claims abstract description 6
- 108090000942 Lactalbumin Proteins 0.000 claims abstract description 6
- 102000007544 Whey Proteins Human genes 0.000 claims description 24
- 108010046377 Whey Proteins Proteins 0.000 claims description 24
- 235000021119 whey protein Nutrition 0.000 claims description 21
- 206010010774 Constipation Diseases 0.000 claims description 12
- 208000007101 Muscle Cramp Diseases 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 7
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 6
- 201000006549 dyspepsia Diseases 0.000 claims description 6
- 208000034783 hypoesthesia Diseases 0.000 claims description 6
- 206010022437 insomnia Diseases 0.000 claims description 6
- 201000009240 nasopharyngitis Diseases 0.000 claims description 6
- 208000002173 dizziness Diseases 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 208000002193 Pain Diseases 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 2
- 230000004596 appetite loss Effects 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 235000021266 loss of appetite Nutrition 0.000 claims 1
- 208000019017 loss of appetite Diseases 0.000 claims 1
- 230000004888 barrier function Effects 0.000 abstract description 5
- 230000001502 supplementing effect Effects 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 230000007358 intestinal barrier function Effects 0.000 abstract description 3
- 230000027119 gastric acid secretion Effects 0.000 abstract description 2
- 210000005027 intestinal barrier Anatomy 0.000 abstract description 2
- 229960005069 calcium Drugs 0.000 description 68
- 235000010755 mineral Nutrition 0.000 description 29
- 235000007319 Avena orientalis Nutrition 0.000 description 23
- 238000010521 absorption reaction Methods 0.000 description 16
- 210000001035 gastrointestinal tract Anatomy 0.000 description 15
- 230000001976 improved effect Effects 0.000 description 14
- 208000008035 Back Pain Diseases 0.000 description 13
- 235000013305 food Nutrition 0.000 description 11
- 239000008280 blood Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 208000006083 Hypokinesia Diseases 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 235000013399 edible fruits Nutrition 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 208000008930 Low Back Pain Diseases 0.000 description 6
- 208000019804 backache Diseases 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 206010061428 decreased appetite Diseases 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 210000000813 small intestine Anatomy 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 235000010208 anthocyanin Nutrition 0.000 description 5
- 239000004410 anthocyanin Substances 0.000 description 5
- 229930002877 anthocyanin Natural products 0.000 description 5
- 150000004636 anthocyanins Chemical class 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- -1 interleukin-l beta Proteins 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 229910001424 calcium ion Inorganic materials 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 108010063045 Lactoferrin Proteins 0.000 description 3
- 102000010445 Lactoferrin Human genes 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 239000005862 Whey Substances 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 3
- 235000021242 lactoferrin Nutrition 0.000 description 3
- 229940078795 lactoferrin Drugs 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 3
- 229960003987 melatonin Drugs 0.000 description 3
- 238000003359 percent control normalization Methods 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 235000014786 phosphorus Nutrition 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 150000004666 short chain fatty acids Chemical class 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 108010023244 Lactoperoxidase Proteins 0.000 description 2
- 102000045576 Lactoperoxidases Human genes 0.000 description 2
- 102100033468 Lysozyme C Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010062519 Poor quality sleep Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 108010050181 aleurone Proteins 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229940069978 calcium supplement Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 229940057428 lactoperoxidase Drugs 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000010891 toxic waste Substances 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 1
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 208000022458 calcium metabolism disease Diseases 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000668 effect on calcium Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000020243 first infant milk formula Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- OVSQVDMCBVZWGM-QCKGUQPXSA-N isoquercetin Natural products OC[C@@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@@H]1O OVSQVDMCBVZWGM-QCKGUQPXSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000036578 sleeping time Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/09—Mashed or comminuted products, e.g. pulp, purée, sauce, or products made therefrom, e.g. snacks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
Abstract
本发明涉及一种预防与改善钙缺乏病的乳钙组合物、其制法及应用,所述预防与改善钙缺乏病的乳钙组合物包括如下原料组分:乳矿物盐、浓缩乳清蛋白、全脂乳粉、牛初乳、低聚果糖、黑果腺肋花楸冻干粉、燕麦β‑葡聚糖、平菇粉、酸樱桃粉。本发明所述的预防与改善钙缺乏病的乳钙组合物,从补充易于吸收的钙,以及改善影响钙吸收性的人体肠道屏障、免疫屏障、胃酸分泌水平等在内的多个影响因素入手,通过各组分的相互配合,协同作用,可有效预防与改善钙缺乏病人群的多种缺钙症状。
Description
技术领域
本发明属于保健食品技术领域,具体涉及一种预防与改善钙缺乏病的乳钙组合物、其制法及应用。
背景技术
正常人体中含钙量为1200~2400g,约占人体质量的1.5%~2.0%,是人体中最多的矿物质元素。其中99%在骨骼和牙齿,另外1%分布于软组织、血浆和细胞外液。钙在维持人体循环、呼吸、神经、内分泌、消化、血液、肌肉、骨骼、泌尿、免疫等各系统正常生理功能中起重要调节作用,尤其是在心肌动作电位的形成中起重要的作用。正常情况下,机体中的钙含量及分布即恒定又平衡。通过骨钙与体液钙的交换,保持了血浆钙的稳定水平。血浆钙由甲状旁腺素、降钙素和维生素D共同调控。另外,体内存在着两个钙浓度梯度,骨-血钙浓度和细胞内外钙浓度梯度。钙是机体不可缺少的营养物质,钙缺乏时,所致体内的钙含量、钙平衡、钙浓度梯度发生变化,造成钙代谢紊乱,导致机体产生的诸多疾病称为钙缺乏病。钙缺乏会给机体带来许多疾病,如骨代谢性疾病、内分泌系统疾病、心脑血管疾病、神经系统疾病、泌尿系统疾病、感受器疾病等。随着年龄的增加,胃肠道吸收机能减弱,肾功能差,户外活动少及骨钙损失加速,造成机体缺钙,及时的补充钙是至关重要的。
食物在胃里经过消化会出现钙离子,人体小肠刷状缘能自动分泌出小分子量的氨基酸或短肽链,遇到从胃里过来的钙离子,则发生螯合反应生成中性的氨基酸螯合钙。这种小分子量的氨基酸螯合钙被小肠以整体形式吸收。吸收后,在细胞里又自动断开螯合键,重新分解成氨基酸和钙离子。通常,通过食物摄入的钙20%~30%被吸收入胃肠道(个体变异性区间为10%~50%),未被吸收的钙随粪便排出体外。吸收量取决于食物中钙的存在形式、存在量及其溶解度,还有饮食中抑制及促进吸收的因素,以及年龄。钙主要在小肠中被吸收(小肠中为酸性环境),而在结肠中吸收程度较小(结肠中偏碱性),结肠中钙吸收伴随细菌性发酵钙从植物性食物中的释放。钙首先在胃中溶解,然后肠腔将影响其生物利用率。目前针对改善缺钙人群的产品多集中在补充钙的含量,忽略了钙的吸收率及其他影响钙吸收与利用的原因,补钙效果并不理想。
发明内容
本发明的目的在于提供一种预防与改善钙缺乏病的乳钙组合物、其制法及应用,所述组合物从补充易于吸收的钙,以及改善影响钙吸收性的人体肠道屏障、免疫屏障、胃酸分泌水平等在内的多个影响因素入手,通过各组分的相互配合,协同作用,可有效预防与改善钙缺乏病人群的多种缺钙症状。
为实现本发明的上述目的,本发明采用以下技术方案:
一种预防与改善钙缺乏病的乳钙组合物,包括如下原料组分:乳矿物盐、浓缩乳清蛋白、全脂乳粉、牛初乳、低聚果糖、黑果腺肋花楸冻干粉、燕麦β-葡聚糖、平菇粉、酸樱桃粉。
优选的,按重量份计,包括如下原料组分:乳矿物盐10-45份、浓缩乳清蛋白12-27份、全脂乳粉8-12份、牛初乳5-13份、低聚果糖13.5-31.5份、黑果腺肋花楸冻干粉1-5份、燕麦β-葡聚糖1-5份、平菇粉0.5-2.5份、酸樱桃粉2-6份。
优选的,按重量份计,包括如下原料组分:乳矿物盐20-40份、浓缩乳清蛋白16-23份、全脂乳粉9-11份、牛初乳7-11份、低聚果糖14-26份、黑果腺肋花楸冻干粉2-4份、燕麦β-葡聚糖2-4份、平菇粉1-2份、酸樱桃粉3-5份。
优选的,按重量份计,包括如下原料组分:乳矿物盐33份、浓缩乳清蛋白20份、全脂乳粉10份、牛初乳9份、低聚果糖16.5份、黑果腺肋花楸冻干粉3份、燕麦β-葡聚糖3份、平菇粉1.5份、酸樱桃粉4份。
乳矿物盐又名乳钙、乳清矿物质浓缩物、乳清钙,乳钙是直接从牛奶中提取出来的天然活性高乳蛋白钙,乳钙中钙主要以磷酸钙,磷酸氢钙和磷酸三钙的形式存在,乳钙中的钙磷比例达2:1,比较有利于人体的吸收,且不需要太多胃酸参与即可分离呈现离子状态,进而被人体直接吸收利用,迅速调节血钙平衡。乳钙的吸收率高达62%~70%,是碳酸钙和葡萄糖酸钙的2.5倍,是乳酸钙的1.75倍,是贝类钙的5.5倍。另外,乳钙中不仅含有钙,还富含丰富的牛奶矿物质,这些成分不仅提供均衡的营养成分,还能促进钙的吸收利用,如磷、镁、乳糖和蛋白质等。其中,乳糖能促进胃肠道中乳酸菌的生长繁殖,促进乳酸发酵过程,使乳糖分解为乳酸。乳酸的形成使胃肠道pH下降,抑制其他腐败菌的生长,提高了胃蛋白酶消化力,进而可促进钙的吸收。在乳糖的辅助下,肠道内钙的吸收率可达到87.33%,比单纯活性钙吸收率高25%。
乳清蛋白是指溶解分散在乳清中的蛋白,约占乳蛋白质的18%~20%,它是较易被消化吸收的高营养价值的优质蛋白质。乳清蛋白的主要成分包括β-乳球蛋白、α-乳白蛋白、牛血清白蛋白、乳铁蛋白、免疫球蛋白、乳过氧化物酶等,这些物质参与构成机体非特异性防御屏障,在抗菌、抗病毒、免疫调节等方面发挥了积极作用。此外还含有高浓度的支链氨基酸-亮氨酸、异亮氨酸、缬氨酸能够参与机体组织的修复和更新,对各种营养和激素信号产生响应,是组织生长和修复所需的重要成分。
牛初乳指的是健康奶牛分娩3d内从乳腺分泌的第一批乳汁,其含有大量的优质蛋白质、矿物质、维生素、生物活性成分以及20多种病原体特异性抗体。牛初乳的蛋白质含有19种氨基酸,包括人体必需8种氨基酸。还含有人体所需的维生素、矿物质。同时含有大量生物活性物质,免疫球蛋白、乳铁蛋白、乳过氧化物酶、胰岛素、溶菌酶以及表皮生长园子、转化生长因子、胰岛素样生长因子、白细胞介素-lβ、白细胞介素-6、干扰素-γ、肿瘤坏死因子-α等各种细胞因子,具有改善胃肠道功能、增进免疫调节、延缓衰老、促进细胞生长发育和加速伤口愈合等多种功能。
黑果腺肋花楸鲜果富含大量生物活性物质,也被称为超级水果,其含有膳食纤维、碳水化合物、蛋白质、有机酸、维生素、矿物质、原花青素、花青素、黄酮醇等营养物质。黑果腺肋花楸果实是植物界多酚和黄酮来源比较丰富的保健食品原料之一,其含有的多酚类化合物能够螯合有毒重金属离子,增加过氧化氢酶、超氧化物歧化酶、谷胱甘肽过氧化物酶和谷胱甘肽过氧化物酶的活性防止细胞大分子氧化损伤,调节肠道炎症水平,改善了肠道屏障功能。黑果腺肋花楸中的花色苷提取物可以有效改善肠道内菌群的平衡、促进有益菌的生长、改善血脂的水平、抑制肝细胞脂肪变性、减少肝脏中重金属的积累、增强胃液分泌和降低胃黏膜血液中血浆的浓度,有一定维持体质代谢平衡和保胃的功能。其次花青色素的代谢物能导致人体血管内皮细胞炎症介质中促炎性细胞因子蛋白质显著减少,从而达到抗炎作用。
燕麦β-葡聚糖是来源于燕麦糊粉、亚糊粉和胚乳组织细胞壁中的无分支线性多糖,属于水溶性纤维,是燕麦中重要的活性成分。燕麦β-葡聚糖可以促进小肠蠕动以及增强益生菌菌株的生长,增加微生物的产量,从而有助于通过粪便去除体内的氮。它还可以增加大便湿重,从而减轻便秘和降低结肠癌的风险。燕麦β-葡聚糖可以通过被厌氧菌分解产酸而降低肠道的pH,增强肠道的酸性环境从而增强抑菌和杀菌作用,以控制病原菌的生长和繁殖。燕麦β-葡聚糖可以通过激活巨噬细胞来增加免疫球蛋白以及自然杀伤细胞等的量来刺激免疫功能,从而提高对癌症、感染以及寄生虫病的抵抗力。
酸樱桃果实营养丰富、均衡,含有大量的维生素(VA、VB、VC)和矿物质(K、Ca、Fe),糖类、脂肪、热量的含量较低,富含花青素、各种花色苷、褪黑激素、槲皮素、异槲皮素和其他有效成分。研究发现它们具有显著的药理作用,如调节睡眠、清除自由基、抗氧化作用、抗炎、镇痛、抗癌、预防心血管疾病、降低血糖、延缓衰老等。酸樱桃果实中富含原花青素,其含量达201.4mg/kg,其具有明显的清除自由基、抗氧化、延缓衰老及修复组织损伤的作用。另外,褪黑激素还是有效的亲脂性抗氧化剂,其清除过氧烷自由基的活性是VE的2倍,是比VE,VC,VD更具有潜力的抗氧化物,与其他自由基清除剂有协同作用。
平菇是人工栽培中适宜性较强、产量较高、药食两用的食用菌,含有蛋白质、总糖、膳食纤维、维生素E、胡萝卜素、烟酸、叶酸、泛酸、维生素A、维生素B12、维生素B1、维生素B2、维生素B6、维生素C、维生素D、磷、钾、钠、铜、锌、硒、镁等营养成分,还包括苏氨酸、缬氨酸、蛋氨酸、异亮氨酸、亮氨酸、苯丙氨酸、赖氨酸、天门冬氨酸、丝氨酸、谷氨酸、甘氨酸、丙氨酸、胱氨酸、酪氨酸、组氨酸、精氨酸等多种游离氨基酸。平菇中有黄酮类、有机酸、几丁质等多种对人体有益的活性成分,具有抗肿瘤、抗氧化、降低胆固醇、调节免疫系统、抗菌、抗病毒、护肝、促进大脑发育等保健功效。
低聚果糖是不能被胃和小肠消化吸收,在大肠中被发酵生成短链脂肪酸。低聚果糖在胃肠中结合金属离子,形成“低聚果糖-矿物质络合物”,进入大肠后,随低聚果糖被双歧杆菌等微生物发酵分解,释放出矿物质(如钙离子、镁离子、锌离子、铜离子等),同时低聚果糖被双歧杆菌等分解产生短链脂肪酸降低了肠道的pH值,在酸性环境中,钙、镁、锌等矿物质溶解度增加,其生物有效性也得到很大提高。此外短链脂肪酸(特别是丁酸)还能刺激结膜细胞生长,因而提高肠黏膜对矿物质的吸收能力,还可以降低β-葡萄糖苷酶的活性,有利于肠内吲哚、亚哨基胺等致癌有毒废物的排除。
本发明所述的组合物的制备方法,具体步骤为:分别取乳矿物盐、浓缩乳清蛋白、全脂乳粉、牛初乳、低聚果糖、黑果腺肋花楸冻干粉、燕麦β-葡聚糖、平菇粉、酸樱桃粉,将各原料混合均匀后,经制粒、干燥、过筛,再加入所得颗粒重量0.8-1.5%的润滑剂,混匀、压片后,即得。所述的润滑剂优选硬脂酸镁。
本发明所述的组合物在预防与改善钙缺乏病的保健食品或药品中的应用。优选的,所述的钙缺乏病的症状表现为四肢麻木、抽筋、腰背疼痛、精神不佳、易感冒、食欲不振、消化不良、便秘、乏力、头晕、失眠中的任意一种。
本发明的有益效果为:
1、本发明提供的组合物,通过采用乳矿物盐、浓缩乳清蛋白、全脂乳粉、牛初乳、低聚果糖、黑果腺肋花楸冻干粉、燕麦β-葡聚糖、平菇粉、酸樱桃粉为原料并进行适合的重量配比,其中:1)牛初乳、乳清蛋白、全脂乳粉、平菇粉与乳矿物盐中的营养物质,提供人体所需钙的同时,促进钙及其他矿物质的吸收,增加了钙的吸收利用率;提供人体所需的必需氨基酸,为胃肠道细胞的修复、增殖与分化提供了充足的原料;增强免疫细胞功能,加速抗体生成,增强巨噬细胞的吞噬能力以及刺激机体淋巴细胞的增殖,提高机体免疫力,改善了抽筋、腰背疼痛、精神不佳、易感冒等症状;2)牛初乳与乳清蛋白中的免疫球蛋白、乳铁蛋白与多种生长因子、低聚果糖、黑果腺肋花楸冻干粉中的花青素与多酚类化合物、酸樱桃粉中的原花青素与褪黑激素、燕麦β-葡聚糖的协同作用,刺激溶菌酶的再生,抑制病原微生物及病毒对肠道物理屏障的破坏;清除自由基,防止脂质过氧化,减少对肠上皮细胞的损伤并促进细胞的增殖分化,调节肠道炎症水平,改善肠道屏障功能;增强胃液分泌,抑制肠道细菌的黏附,提高肠粘膜对矿物质的吸收,有利于肠内有毒废物的排出;降低肠道的pH,增强肠道的酸性环境,增强抑菌和杀菌作用,促进益生菌的增殖;促进小肠的蠕动,增加大便湿重,促进粪便的排出,进而改善食欲不振、消化不良、便秘、乏力、睡眠不佳等症状。
2、本发明可有效改善钙缺乏病人群包括抽筋、腰背疼痛、乏力、食欲减退、便秘、失眠等在内的多种缺钙症状,有效率达89%以上,补钙效果好,成分安全,不添加蔗糖、麦芽糊精、色素、香精等辅料,奶香味纯正,口感自然,安全可靠,可作为长期食用以改善钙缺乏病的保健食品。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚,下面将对本发明的技术方案进行详细的描述。显然,所描述的实施例仅仅是本发明的一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动的前提下所得到的所有其它实施方式,都属于本发明所保护的范围。以下实施例中以1份代表1g。
实施例1
一种预防与改善钙缺乏病的乳钙组合物片剂,由如下原料组分制成:乳矿物盐10份、浓缩乳清蛋白27份、全脂乳粉8份、牛初乳13份、低聚果糖31.5份、黑果腺肋花楸冻干粉1份、燕麦β-葡聚糖1份、平菇粉2.5份、酸樱桃粉6份;
制备方法为:分别取乳矿物盐、浓缩乳清蛋白、全脂乳粉、牛初乳、低聚果糖、黑果腺肋花楸冻干粉、燕麦β-葡聚糖、平菇粉、酸樱桃粉,将各原料混合均匀后,经制粒、干燥、过筛,再加入颗粒重量0.8%的润滑剂,混匀、压片后,即得。
实施例2
一种预防与改善钙缺乏病的乳钙组合物片剂,由如下原料组分制成:乳矿物盐20份、浓缩乳清蛋白23份、全脂乳粉9份、牛初乳11份、低聚果糖26份、黑果腺肋花楸冻干粉2份、燕麦β-葡聚糖2份、平菇粉2份、酸樱桃粉5份;
制备方法为:分别取乳矿物盐、浓缩乳清蛋白、全脂乳粉、牛初乳、低聚果糖、黑果腺肋花楸冻干粉、燕麦β-葡聚糖、平菇粉、酸樱桃粉,将各原料混合均匀后,经制粒、干燥、过筛,再加入颗粒重量1.5%的润滑剂,混匀、压片后,即得。
实施例3
一种预防与改善钙缺乏病的乳钙组合物片剂,由如下原料组分制成:乳矿物盐33份、浓缩乳清蛋白20份、全脂乳粉10份、牛初乳9份、低聚果糖16.5份、黑果腺肋花楸冻干粉3份、燕麦β-葡聚糖3份、平菇粉1.5份、酸樱桃粉4份;
制备方法为:分别取乳矿物盐、浓缩乳清蛋白、全脂乳粉、牛初乳、低聚果糖、黑果腺肋花楸冻干粉、燕麦β-葡聚糖、平菇粉、酸樱桃粉,将各原料混合均匀后,经制粒、干燥、过筛,再加入颗粒重量1%的润滑剂,混匀、压片后,即得。
实施例4
一种预防与改善钙缺乏病的乳钙组合物片剂,由如下原料组分制成:乳矿物盐40份、浓缩乳清蛋白16份、全脂乳粉11份、牛初乳7份、低聚果糖14份、黑果腺肋花楸冻干粉4份、燕麦β-葡聚糖4份、平菇粉1份、酸樱桃粉3份;制备方法同实施例3。
实施例5
一种预防与改善钙缺乏病的乳钙组合物片剂,由如下原料组分制成:乳矿物盐45份、浓缩乳清蛋白12份、全脂乳粉12份、牛初乳5份、低聚果糖13.5份、黑果腺肋花楸冻干粉5份、燕麦β-葡聚糖5份、平菇粉0.5份、酸樱桃粉2份;制备方法同实施例3。
对比例1
一种预防与改善钙缺乏病的乳钙组合物片剂,由如下原料组分制成:乳矿物盐33份、浓缩乳清蛋白20份、全脂乳粉10份、牛初乳9份、低聚果糖19.5份、黑果腺肋花楸冻干粉3份、平菇粉1.5份、酸樱桃粉4份。制备方法同实施例3。
对比例2
一种预防与改善钙缺乏病的乳钙组合物片剂,由如下原料组分制成:浓缩乳清蛋白20份、全脂乳粉10份、牛初乳9份、低聚果糖49.5份、黑果腺肋花楸冻干粉3份、燕麦β-葡聚糖3份、平菇粉1.5份、酸樱桃粉4份。制备方法同实施例3。
对比例3
一种预防与改善钙缺乏病的乳钙组合物片剂,由如下原料组分制成:乳矿物盐33份、全脂乳粉20份、全脂乳粉10份、牛初乳9份、低聚果糖19.5份、燕麦β-葡聚糖3份、平菇粉1.5份、酸樱桃粉4份。制备方法同实施例3。
试验例
征集有钙缺乏症一般症状(四肢麻木、抽筋、腰背疼痛、精神不佳、易感冒、食欲不振、消化不良、便秘、乏力、头晕、失眠)中至少有一项者共110人,年龄在30-75岁之间,男性56名,女性54名,随机分为4组,分别为试验组、对照组1、对照组2与对照组3,试验组28人,对照组1 27人,对照组2 27人,对照组3 28人。试验组志愿者食用实施例3得到的组合物,每天2次,每次1片;对照组1志愿者食用对比例1得到的组合物,每天2次,每次1片;对照组2志愿者食用对比例2得到的组合物,每天2次,每次1片;对照组3志愿者食用对比例3得到的组合物,每天2次,每次1片;连续食用6个月,对各组志愿者进行检查记录,统计结果,结果见表1。
改善:四肢麻木、抽筋、腰背疼痛、精神不佳、易感冒、食欲不振、消化不良、便秘、乏力、头晕、失眠11项中主要临床症状有1种以上改善,且无其他不良反应。
无效:四肢麻木、抽筋、腰背疼痛、精神不佳、易感冒、食欲不振、消化不良、便秘、乏力、头晕、失眠11项中主要临床症状没有改善,或者是有不良反应。
有效率为改善人数与每组总人数的百分比。
表1试验结果
组别 | 有效(人) | 无效(人) | 有效率(%) |
试验组 | 25 | 3 | 89.3% |
对照组1 | 22 | 5 | 81.5% |
对照组2 | 19 | 8 | 70.4% |
对照组3 | 18 | 10 | 64.3% |
从1表可以看出,本发明所提供的的预防与改善钙缺乏病的组合物对钙缺乏人群具有明显的改善作用,而对照组中由于仅仅含有其中部分成分,其改善效果远远不及试验组,与对照组1相比,试验组的有效率提高了7.8%,与对照组2相比,试验组的有效率提高了18.9%,与对照组3相比,试验组的有效率提高了25%,效果显著。其中抽筋、四肢麻木、腰背疼痛、乏力的改善尤为突出。以上结果说明了,本发明提供的组合物各组分相互作用,协同提高了预防与改善钙缺乏病的效果。
典型案例
1、李某,女,55岁,脚后跟疼、乏力、多梦,有点便秘,食用本发明实施例3得到的预防与改善钙缺乏病的组合物,每天2片,食用1周后,脚后跟疼痛减轻,继续服用1个月,便秘得到改善,人也有精神了,睡眠质量也提高了。
2、王某,女,63岁,高血压、食欲差、易感冒、睡眠质量差、注意力不集中,食用本发明实施例3得到的预防与改善钙缺乏病的组合物,每天2片,食用15天,食欲增强,每天多吃半碗饭。继续食用10天,睡眠时间增加1小时,面色也红润了,感冒次数减少。
3、刑某,男,69岁,关节疼痛、乏力、血钙值稍低于正常值,服用食用本发明实施例1得到的预防与改善钙缺乏病的组合物,每天2片,食用1个月后,关节疼痛减轻,血钙值为2.3mmoL/L。继续食用2个月,乏力感消失,能出门多走动了。
4、范某,男33岁,早上起来脚趾经常抽筋、乏力,睡眠时多梦,用食用本发明实施例2得到的预防与改善钙缺乏病的组合物,每天2片,食用1周,抽筋情况消失,继续食用2月,睡眠情况改善,多梦次数减少。
5、刘某,女47岁,便秘、面色发黄、慢性胃炎、关节疼,食用食用本发明实施例3得到的预防与改善钙缺乏病的组合物,每天2片,食用10天,便秘现象改善,排便由之前的3天1次改善为2天1次,同时关节疼痛缓解。继续食用25天,面色红润,食欲增强,腹胀感改善。
以上所述,仅为本发明的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,可轻易想到变化或替换,都应涵盖在本发明的保护范围之内。因此,本发明的保护范围应以所述权利要求的保护范围为准。
Claims (8)
1.一种预防与改善钙缺乏病的乳钙组合物,其特征在于,包括如下原料组分:
乳矿物盐、浓缩乳清蛋白、全脂乳粉、牛初乳、低聚果糖、黑果腺肋花楸冻干粉、燕麦β-葡聚糖、平菇粉、酸樱桃粉。
2.根据权利要求1所述的预防与改善钙缺乏病的乳钙组合物,其特征在于,按重量份计,包括如下原料组分:
乳矿物盐10-45份、浓缩乳清蛋白12-27份、全脂乳粉8-12份、牛初乳5-13份、低聚果糖13.5-31.5份、黑果腺肋花楸冻干粉1-5份、燕麦β-葡聚糖1-5份、平菇粉0.5-2.5份、酸樱桃粉2-6份。
3.根据权利要求1所述的预防与改善钙缺乏病的乳钙组合物,其特征在于,按重量份计,包括如下原料组分:
乳矿物盐20-40份、浓缩乳清蛋白16-23份、全脂乳粉9-11份、牛初乳7-11份、低聚果糖14-26份、黑果腺肋花楸冻干粉2-4份、燕麦β-葡聚糖2-4份、平菇粉1-2份、酸樱桃粉3-5份。
4.根据权利要求1所述的预防与改善钙缺乏病的乳钙组合物,其特征在于,按重量份计,包括如下原料组分:
乳矿物盐33份、浓缩乳清蛋白20份、全脂乳粉10份、牛初乳9份、低聚果糖16.5份、黑果腺肋花楸冻干粉3份、燕麦β-葡聚糖3份、平菇粉1.5份、酸樱桃粉4份。
5.权利要求1-4之一所述的预防与改善钙缺乏病的乳钙组合物的制备方法,其特征在于,具体步骤为:分别取乳矿物盐、浓缩乳清蛋白、全脂乳粉、牛初乳、低聚果糖、黑果腺肋花楸冻干粉、燕麦β-葡聚糖、平菇粉、酸樱桃粉,将各原料混合均匀后,经制粒、干燥、过筛,再加入所得颗粒重量0.8-1.5%的润滑剂,混匀、压片后,即得。
6.根据权利要求5所述的预防与改善钙缺乏病的乳钙组合物的制备方法,其特征在于,所述的润滑剂为硬脂酸镁。
7.权利要求1-4之一所述的预防与改善钙缺乏病的乳钙组合物在制备预防与改善钙缺乏病的保健食品或药品中的应用。
8.根据权利要求7所述的应用,其特征在于,所述的钙缺乏病的症状表现为四肢麻木、抽筋、腰背疼痛、精神不佳、易感冒、食欲不振、消化不良、便秘、乏力、头晕、失眠中的任意一种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210572582.5A CN114947138A (zh) | 2022-05-25 | 2022-05-25 | 一种预防与改善钙缺乏病的乳钙组合物、其制法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210572582.5A CN114947138A (zh) | 2022-05-25 | 2022-05-25 | 一种预防与改善钙缺乏病的乳钙组合物、其制法及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114947138A true CN114947138A (zh) | 2022-08-30 |
Family
ID=82955259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210572582.5A Pending CN114947138A (zh) | 2022-05-25 | 2022-05-25 | 一种预防与改善钙缺乏病的乳钙组合物、其制法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114947138A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115644451A (zh) * | 2022-09-30 | 2023-01-31 | 内蒙古伊利实业集团股份有限公司 | 一种矿物质组合物及其产品和应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103976359A (zh) * | 2014-05-23 | 2014-08-13 | 汤臣倍健股份有限公司 | 食品营养强化组合物及其应用、保健食品及其制备方法 |
CN106579460A (zh) * | 2016-12-23 | 2017-04-26 | 上海奥医生物医药科技有限公司 | 一种骨折专用型临床营养配方及其制备方法 |
CN108719970A (zh) * | 2018-04-24 | 2018-11-02 | 海南久惠生物科技有限公司 | 一种增加骨密度的组合物、包含其的保健品及其制备方法 |
CN109090319A (zh) * | 2018-08-31 | 2018-12-28 | 迪拜尔特控股(北京)有限公司 | 乳矿物盐压片糖果 |
CN110839703A (zh) * | 2019-11-29 | 2020-02-28 | 亨美久健康科技(广东)有限公司 | 一种营养组合物及其制备方法 |
CN114468290A (zh) * | 2022-03-11 | 2022-05-13 | 河南磐康健康管理股份有限公司 | 一种预防与改善缺硒引起的慢性病的组合物及制备方法 |
-
2022
- 2022-05-25 CN CN202210572582.5A patent/CN114947138A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103976359A (zh) * | 2014-05-23 | 2014-08-13 | 汤臣倍健股份有限公司 | 食品营养强化组合物及其应用、保健食品及其制备方法 |
CN106579460A (zh) * | 2016-12-23 | 2017-04-26 | 上海奥医生物医药科技有限公司 | 一种骨折专用型临床营养配方及其制备方法 |
CN108719970A (zh) * | 2018-04-24 | 2018-11-02 | 海南久惠生物科技有限公司 | 一种增加骨密度的组合物、包含其的保健品及其制备方法 |
CN109090319A (zh) * | 2018-08-31 | 2018-12-28 | 迪拜尔特控股(北京)有限公司 | 乳矿物盐压片糖果 |
CN110839703A (zh) * | 2019-11-29 | 2020-02-28 | 亨美久健康科技(广东)有限公司 | 一种营养组合物及其制备方法 |
CN114468290A (zh) * | 2022-03-11 | 2022-05-13 | 河南磐康健康管理股份有限公司 | 一种预防与改善缺硒引起的慢性病的组合物及制备方法 |
Non-Patent Citations (1)
Title |
---|
周惠明等: "半干旱地区森林培育技术研究", vol. 1, 华南理工大学出版社, pages: 273 - 274 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115644451A (zh) * | 2022-09-30 | 2023-01-31 | 内蒙古伊利实业集团股份有限公司 | 一种矿物质组合物及其产品和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6262019B1 (en) | Method of treatment of glutathione deficient mammals | |
US6900173B2 (en) | Perioperative multivitamin protein bar for use in preparing an individual for fast surgical recovery | |
US20040253227A1 (en) | Perioperative multivitamin protein beverage and additive for use in preparing an individual for fast surgical recovery | |
CN108685100B (zh) | 一种复合短肽粉配方及其制备方法 | |
JP5315996B2 (ja) | 総合経腸栄養組成物 | |
KR101539382B1 (ko) | 장 기능 개선 및 배변 촉진용 식품 조성물 | |
CN112772813A (zh) | 一种提高免疫力缓解疲劳的复合肽固体饮料及其制备方法 | |
JP4231208B2 (ja) | 骨粗鬆症の予防のための発酵乳由来の栄養補助食品 | |
CN105815514A (zh) | 藜麦减肥奶茶 | |
CN103190483A (zh) | 儿童成长奶茶 | |
US20050013884A1 (en) | Compositions and methods for treating heart disease | |
WO2008095093A2 (en) | Method of increasing cellular function and health of glutathione deficient animals | |
CN114947138A (zh) | 一种预防与改善钙缺乏病的乳钙组合物、其制法及应用 | |
KR20110119305A (ko) | 타우린, 비타민류, 로얄젤리, 홍삼, 구기자, 글루메이트 (탈지미강, 미베아) 및 애플 에센스를 주성분으로 함유하는 기능성 음료조성물 | |
CN101755878B (zh) | 一种含有苦瓜山楂决明子的减肥蛋糕的制备方法 | |
CN114617169A (zh) | 一种预防和降低高血压、血糖和血脂的奶粉 | |
CN110584120A (zh) | 骨健康组合物 | |
KR20200043555A (ko) | 다이어트용 보조식품 조성물 | |
CN114680339A (zh) | 一种改善肌肉衰减延缓衰老的营养补充剂及其应用 | |
CN107712875A (zh) | 黑藜麦减肥代餐 | |
CN103330118A (zh) | 减肥药物 | |
CN115486482A (zh) | 一种有益于心血管健康的牦牛配方奶粉 | |
CN111084317A (zh) | 一种保健型固体饮料及其制备方法 | |
CN110089751A (zh) | 肠排保健品 | |
CN116584545B (zh) | 一种调制羊奶粉及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220830 |